22UA:ETR
BioNTech SE - ADR
€86.05
arrow_downward
-0.98%(-0.85) 1D
Oct 2, 5:35:31 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€86.15
High
€86.90
Low
€85.55
Mkt. cap
24.34B
Avg. vol.
34.80K
Volume
27.69K
52-wk high
€105.70
52-wk low
€68.30
No. of employees
8K
Open
€86.15
High
€86.90
Low
€85.55
Mkt. cap
24.34B
Avg. vol.
34.80K
Volume
27.69K
52-wk high
€105.70
52-wk low
€68.30
No. of employees
8K
News stories
From web sources and news partners
Stock Titan
·
46 minutes ago
BioNTech (BNTX) CEO sells 17,000 shares twice under a preset trading plan
AD HOC NEWS
·
4 hours ago
BioNTech stock after-hours at EUR 86.05: minus 0.12 percent versus prior close
AD HOC NEWS
·
6 hours ago
Morgan Stanley sets USD 115 target for BioNTech stock
AD HOC NEWS
·
1 day ago
BioNTech stock after-hours at EUR 87.00: plus 0.29 percent
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR